- PeptiDream has increased its operating income forecast for the fiscal year from 10.50 billion yen to 20.10 billion yen.
- The company’s estimated operating income was 18.93 billion yen, thus beating the estimates.
- The newly projected net income is 14.00 billion yen, up from the earlier prediction of 7.30 billion yen.
- Net sales are now expected to reach 45.00 billion yen, an increase on the former figure of 35.00 billion yen.
- There is still no dividend predicted.
- PeptiDream’s first quarter results showed an operational loss of 1.10 billion yen and a net loss of 842.0 million yen.
- Net sales for the first quarter stood at 4.23 billion yen, marking a 15% decrease year on year.
- Revenue for Drug Discovery and Development was 521.2 million yen, a 47% decrease year on year. At the same time, Radiopharmaceutical revenue was 3.78 billion yen, a 5.2% decrease year on year.
- An expansion of a partnership with Novartis in peptide drug discovery is predicted to contribute more to revenue than initially expected.
- All forecasted elements – including revenue, Core operating profit, operating profit, profit before tax, and profit attributable to owners – are expected to exceed initial predictions.
- On April 29, 2024, PeptiDream and Novartis signed an agreement to expand their collaboration in peptide drug discovery. As a result, the company is set to receive an upfront payment of $180 million from Novartis.
- This agreement’s completion is subject to the receipt of necessary approvals from both companies and waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1964.
- There are 5 buys and 1 hold rating on the stock, with no sells.
Peptidream Inc on Smartkarma
Analyst coverage of Peptidream Inc on Smartkarma reveals valuable insights for investors. Tina Banerjee, a top independent analyst, published a bullish report titled “Peptidream (4587 JP): Steadily Riding the Next Wave of Drug Discovery“. In the report, it is highlighted that Peptidream obtained approval for the first human trial of a radiopharma targeting renal cell carcinoma. Additionally, an expanded collaboration with Novartis could potentially result in a substantial $2.7 billion milestone payment to Peptidream. The company’s impressive performance in 2023, with a 7% year-over-year revenue increase to ¥29 billion, particularly driven by a 40% growth in radiopharmaceutical revenue to ¥16 billion, sets a positive trajectory for future growth.
A look at Peptidream Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 2 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
PeptiDream Inc. is a biopharmaceutical company dedicated to enhancing patient outcomes through the development of peptide therapeutics. By focusing on peptides, which are short chains of amino acids, the company aims to create innovative solutions to address unmet medical needs. Leveraging its expertise in peptide drug discovery, PeptiDream Inc. is positioned to drive sustainable growth in the healthcare sector.
Assessing PeptiDream Inc.’s long-term outlook using Smartkarma Smart Scores reveals a mixed perspective. While the company demonstrates strong momentum in its operations, with a high score in this aspect, other factors such as value, dividend, and growth show more moderate ratings. However, PeptiDream Inc. has displayed resilience, garnering a notable score in this area. Overall, the company’s strategic focus on peptide therapeutics and its impressive momentum highlight potential opportunities for future growth and success in the biopharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
